The 3rd Conference on Innovations in Tuberculosis 2026 will take place on 11 May 2026 in Dar es Salaam, Tanzania, as a pre-meeting of the 20th INTEREST 2026.

This meeting will spotlight cutting-edge advances in tuberculosis prevention, vaccination, and treatment, while confronting ongoing challenges such as MDR-TB and inequitable access through focused discussions on implementation in African healthcare settings. We invite you to share your expertise and help shape a strong, impactful scientific programme. Your perspectives will spark meaningful dialogue and support practical solutions to the challenges facing the region.

The goal of the Conference is to deliver a high-quality program on innovations in Tuberculosis with an emphasis on region-specific needs. It aims to provide a platform for scientific interchange, education, and fostering collaborations to advance the field. More specifically, the program is aimed to:

• Create an African dissemination platform for an unbiased, scientific exchange and education regarding clinically relevant advances in Tuberculosis;
• Provide educational settings to discuss the clinical translation of recent developments considering regional epidemic patterns and healthcare systems;
• Share real-world experience and facilitate evidence-based program implementation;
• Foster new and lasting cross-disciplinary collaborations aiming to strengthen Tuberculosis research and management in high-disease-burden regions;
• Encourage early-career investigators to actively participate in the program and support their career trajectory toward future leaders in Tuberculosis research.

The organizers welcome abstracts that explore a wide range of topics, including but not limited to:

• TB screening & Asymptomatic TB
• TB in pregnancy, Maternal TB
• Drug-Resistant TB Treatment
• Pediatric TB
• New TB Drugs and Trials of Combination Regimens
• TB Treatment Monitoring
• AI and Big Data in TB Research and/or Program Implementation
• TB Clinical Management, including Advanced HIV
• TB Comorbidities, and Coinfections
• Post-TB Lung Disease
• Biomarkers

Important: Abstract submitters are strongly encouraged to use person-first language in their submissions. View the video tutorial and guidelines here.

Abstract Submission Deadline: Friday, 13 February 2026